EyePoint appoints Jay S. Duker as COO; $500K base, 305K options

EyePoint, Inc.

Appointed Jay S. Duker, M.D. as COO effective Nov. 1, 2021; he had served as part-time Chief Strategic Scientific Officer since July 2020.
Annual base salary of $500,000; eligible for target annual bonus of 50% of base salary based on performance.
Granted options to purchase 305,000 shares at $11.47, vesting over 4 years; received 15,258 RSUs valued at $175,000 vesting in 1 year.
Received one-time cash award of $175,000 subject to repayment if terminated for cause within one year.
Dr. Duker previously chaired ophthalmology at Tufts Medical Center and co-founded three start-ups including Hemera Biosciences.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jay S. Duker

Chief Operating Officer

EYPT · EyePoint, Inc.

Effective: 2021-11-01
Filed: November 1, 2021, 7:59 PM ET

On November 1, 2021 (the “ COO Start Date ”), EyePoint Pharmaceuticals , Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jay S. Duker was appointed as Chief Operating Officer at EyePoint, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On November 1, 2021 (the “ COO Start Date ”), EyePoint Pharmaceuticals , Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-053039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.